関連する実験動画
Updated: May 27, 2026
07:46
Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
Published on: October 16, 2010
ビタミンCは高血圧患者の上心冠動脈の内皮機能不全を改善する
U Solzbach1, B Hornig, M Jeserich
1Medical Clinic, Department of Cardiology, University of Freiburg, Germany.
Circulation
|October 7, 1997
まとめ
ビタミンCのサプリメントは,血管収縮を軽減し,血管拡張を高めることで,高血圧患者の冠動脈機能を改善しました. これは,酸化ストレスが高血圧における内皮機能不全に寄与することを示唆しています.
科学分野:
- 心臓病学 心臓病学
- 血管生物学 血管生物学
- 栄養科学とは,栄養科学である.
背景:
- 高血圧は,フリーラジカルの形成の増加と関連しており,窒素酸化物 (NO) の機能と冠動脈内皮の健康を損なう可能性があります.
- 酸化ストレスはNOを無活性化させ,高血圧の個人に内皮機能不全を引き起こす可能性があります.
研究 の 目的:
- 抗酸化物質のビタミンCが,高血圧患者の冠動脈における内皮機能を改善できるかどうかを調査する.
- ビタミンCが,高血圧における血管機能に対する酸化ストレスによる負の効果に対抗できるという仮説を検証する.
主な方法:
- 冠動脈疾患のない22人の高血圧患者は,左前垂下冠動脈 (LAD) の内皮に依存する応答の評価を受けた.
- アセチルコリンとフロー依存性血管拡張 (FDD) に対する血管反応は,静脈内ビタミンCまたはプラセボ輸液の前後に測定されました.
- 定量冠動脈血管撮影は,LAD光領域の変化を分析するために使用されました.
主要な成果:
- ビタミンCは高血圧患者のアセチルコリンに対する静脈縮反応を著しく低下させた.
- ビタミンCは,冠動脈における流量依存性血管拡張 (FDD) を著しく増加させた.
- ドップラー流速にビタミンCの有意な影響は見られなかった.
結論:
- ビタミンCの投与は,高血圧患者の冠動脈の内皮に依存する血管運動能力を高めます.
- この発見は,高血圧患者の内皮機能不全を引き起こす酸化ストレスの増加の役割を支持しています.
関連する概念動画
01:23Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
01:30Coronary Artery Disease I: Introduction
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
01:26Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
01:26Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...